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Neurotrophins, the cognate ligands for the Trk recep-
tors, are homodimers and induce Trk dimerization
through a symmetric bivalent mechanism. We report
here that amitriptyline, an antidepressant drug,
directly binds TrkA and TrkB and triggers their dimer-
ization and activation. Amitriptyline, but not any other
tricyclic or selective serotonin reuptake inhibitor anti-
depressants, promotes TrkA autophosphorylation
in primary neurons and induces neurite outgrowth
in PC12 cells. Amitriptyline binds the extracellular
domain of both TrkA and TrkB and promotes
TrkA-TrkB receptor heterodimerization. Truncation
of amitriptyline binding motif on TrkA abrogates the
receptor dimerization by amitriptyline. Administra-
tion of amitriptyline to mice activates both receptors
and significantly reduces kainic acid-triggered
neuronal cell death. Inhibition of TrkA, but not TrkB,
abolishes amitriptyline’s neuroprotective effect
without impairing its antidepressant activity. Thus,
amitriptyline acts as a TrkA and TrkB agonist and
possesses marked neurotrophic activity.
INTRODUCTION
Neurotrophins, which include nerve growth factor (NGF), brain-
derived neurotrophic factor (BDNF), NT-3, and NT-4/5, are crit-
ical for the development and maintenance of the peripheral
and the central nervous systems. Neurotrophins exert their phys-
iological actions through two classes of receptors: Trk tyrosine
kinase receptors and p75NTR. The Trk receptors are members
of a transmembrane tyrosine kinases family (TrkA, TrkB, and
TrkC). NGF primarily binds TrkA, BDNF and NT-4/5 mainly
interact with TrkB, and NT-3 predominantly associates with
TrkC, while having weaker interactions with TrkA and TrkB
receptors. Docking of neurotrophic factors on Trk receptors initi-
ates receptor homodimerization, autophosphorylation of cyto-
plasmic tyrosine residues on the receptors, and a cascade of
cell signaling events including Ras/Raf/MAP kinase, PI3K/Akt,644 Chemistry & Biology 16, 644–656, June 26, 2009 ª2009 Elsevierand PLC-g1 (Kaplan and Stephens, 1994). These signals prevent
apoptotic cell death, promote cellular differentiation and axon
elongation, and upregulate choline acetyl transferase. Several
neuronal cell types that are lost in certain pathologies express
TrkA and respond toNGF, andNGF has been reported to reverse
basal forebrain cholinergic atrophy, reduce cognitive decline,
stimulate cholinergic fiber growth in humans with mild Alz-
heimer’s disease (Mufson et al., 2008), and ameliorate peripheral
diabetic neuropathies (Apfel, 2002). Other applications pro-
posed for NGF include treatment of neuronal damage (Hughes
et al., 1997) and targeting of neuroectoderm-derived tumors
(Cortazzo et al., 1996; LeSauteur et al., 1995). In addition, neuro-
trophins such as BDNF act as key regulators of neurite
outgrowth and synaptic plasticity, and it has been proposed
that a deficit of these molecules may underlie the psychopa-
thology of stress and depression, while antidepressants may
act via neurotrophins to produce the molecular and behavioral
changes associated with their efficacy (Altar et al., 1997; Duman
et al., 1997). Thus, both NGF and BDNF might contribute to anti-
depressant-induced formation and stabilization of synaptic
connectivity.
Nonetheless, the use of NGF for the treatment of these
diseases has been limited by its poor pharmacological proper-
ties, such as the low blood-brain barrier permeability (Poduslo
and Curran, 1996) and relevant side effects, like hyperalgesia
(Apfel, 2002). To search for NGF and BDNF mimetics with better
pharmacokinetic properties, tremendous efforts have been
made to design small, proteolytically stable molecules with neu-
rotrophic activity and specificity for TrkA or TrkB. For example,
ligandmimicry and antibodymimicry strategies have been inten-
sively explored to generate peptide analogues of two agonists
directed to the extracellular domain (ECD) of TrkA or TrkB
(Beglova et al., 2000; O’Leary and Hughes, 2003; Saragovi et al.,
1991; Xie et al., 2000). Additionally, an NGF-mimetic peptide has
recently been reported to partially mimic NGF and reduce neuro-
pathic pain in rat (Colangelo et al., 2008). However, none of these
antibodies and peptidomimetics can fully mimic NGF or BDNF
function in animals.
In this paper, we show that tricyclic antidepressant amitripty-
line, which is traditionally thought to exert its therapeutic effects
via blockade of the serotonin and noradrenaline transporters,
interacts directly with both TrkA and TrkB receptors on theLtd All rights reserved
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TrkB homo- and heterodimerization and activation in mouse
brain, but that the heterodimerization is not required for Trk
receptor activation. Truncation of amitriptyline binding motif on
TrkA but not the corresponding region on TrkB abolishes the
receptor homo- and heterodimerization. Moreover, amitriptyline
suppresses neuronal apoptosis elicited by kainic acid (KA) in
a TrkA-dependent manner. Hence, amitriptyline acts as a TrkA
and TrkB receptor agonist and possesses marked neurotrophic
activity.
RESULTS
Amitriptyline Selectively Protects Hippocampal
Neurons from Apoptosis
Recently, we developed a cell-based screening approach for
novel TrkA agonist discovery and reported that gambogic amide
Figure 1. Amitriptyline Selectively Protects
Hippocampal Neurons from Apoptosis
(A) Chemical Structures of tricyclic antidepressant
drugs.
(B) Some of the tricyclic antidepressant drugs
protect T17-TrkA cells but not parental SN56 cells
from apoptosis.
(C) EC50 titration assays for promoting T17 cell
survival. TrkA-overexpressing T17 cells were pre-
treated with various tricyclic antidepressant drugs
for 30min, followed by 1 mMstaurosporine for 9 hr.
Apoptosis was quantitatively analyzed. EC50
values are the drug concentrations, which prevent
50% of cells from apoptosis.
(D) Amitriptyline selectively prevents apoptosis in
hippocampal neurons. Hippocampal neurons
were pretreated with NGF (100 ng/ml), gambogic
amide, and various tricyclic antidepressant drugs
(0.5 mM) for 30 min, followed by 50 mM glutamate
for 16 hr. Apoptosis was quantitatively analyzed.
(E) Amitriptyline prevents OGD-provoked neuronal
apoptosis in hippocampal neurons. Hippocampal
neurons were pretreated with various drugs
(0.5 mM) for 30 min, followed by OGD for 3 hr.
Apoptosis was quantitatively analyzed (left). Data
represent the mean ± SEM of n = 4–5; one-way
ANOVA, followed by Dunnett’s test, *p < 0.01;
**p < 0.005.
is a selective agonist for TrkA that
possesses robust neurotrophic activity
and prevents neuronal cell death (Jang
et al., 2007). During the screening,we also
surprisingly identified numerous tricyclic
antidepressant compounds that selec-
tively protected TrkA-expressing T17
cells but not parental SN56 cells lacking
TrkA from apoptosis (Figures 1A and
1B). Titration assays with T17 cells for
apoptosis inhibitory activity revealed that
EC50 values were 8, 30, and 50 nM for
clomipramine, imipramine, and amitripty-
line, respectively (Figure 1C). TrkA and
p75NTR are upregulated in hippocampal
and cortical neurons under pathophysiological conditions
(Kokaia et al., 1998; Lee et al., 1998). Moreover, neuroprotective
effects of NGF in hippocampal and cortical neurons have been
demonstrated in vitro and in vivo (Culmsee et al., 1999; Zhang
et al., 1993). Therefore, to test whether the tricyclic compounds
can also protect primary hippocampal neurons from apoptosis,
we pretreated primary cultures with test compounds (0.5 mM
each) for 30min, followed by glutamate treatment. NGF, gambo-
gic amide, or amitriptyline pretreatment significantly protected
hippocampal neurons from apoptosis, while other tricyclic drugs
tested had no effect (Figure 1D and data not shown).
NGF reduces cortical infarction and apoptosis in transgenic
mice and protects PC12 cells from apoptosis in oxygen-glucose
deprivation (OGD) (Beck et al., 1992; Guegan et al., 1998). To
explore whether amitriptyline and/or other tricyclics could
protect hippocampal neurons from OGD-provoked apoptosis,
we pretreated primary cultures with various tricyclic drugs,
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suppressed apoptosis, whereas neither imipramine nor clomipr-
amine exhibited any protective activity (Figure 1E, left). Titration
assays showed that amitriptyline repressed neuronal apoptosis
in a dose-dependent manner (Figure 1E, right). Thus, amitripty-
line but not any other tricyclic antidepressant drugs selectively
protects hippocampal neurons from apoptosis.
Amitriptyline Activates TrkA and its Downstream
Signaling Cascades
NGF binds TrkA and elicits its autophosphorylation and down-
stream MAP kinase and PI3K/Akt pathway activation in primary
hippocampal and cortical cultures that express demonstrable
TrkA (Culmsee et al., 2002; Kume et al., 2000). To explore
whether amitriptyline could stimulate TrkA, we treated hippo-
campal neurons with 0.5 mM amitriptyline or other tricyclic drugs
for 30 min. Immunofluorescent staining showed that amitripty-
Figure 2. Amitriptyline Activates the TrkA
Receptor and its Downstream Signaling
Cascades
(A) Amitriptyline activates TrkA in hippocampal
neurons. Hippocampal neurons were treated
with NGF (100 ng/ml) or various tricyclic antide-
pressant drugs (500 nM) for 30 min. Immunofluo-
rescent staining was conducted with anti-p-TrkA
antibody.
(B) Amitriptyline activates TrkA downstream
signaling cascades including Akt and MAP
kinases. Hippocampal neurons were treated as
described above. The cell lysates were analyzed
by immunoblotting with various antibodies.
(C) Trk receptor inhibitor K252a (100 nM) blocks
amitriptyline-provoked TrkA and TrkB activation.
Data represent mean ± SEM (One-way ANOVA,
Dunnett’s test, *p < 0.001).
(D) Akt and MAP kinase activation kinetics and
dosage assays by amitriptyline. Hippocampal
neurons were treated with 500 nM amitriptyline
for various time points. The cell lysates were
analyzed by immunoblotting with various anti-
bodies.
line, like NGF, triggered TrkA tyrosine
phosphorylation, whereas other tricyclic
compounds did not (Figure 2A). Both
Akt and Erk1/2 were markedly activated
in NGF- or amitriptyline-treated hippo-
campal neurons. In contrast, none of the
other tricyclic drugs was capable of
simultaneously activating Akt and Erk1/
2 (Figure 2B). It was worth noting that
amitriptyline induced TrkA phosphoryla-
tion on both tyrosine Y751 and Y794.
Surprisingly, Y490 was not phosphory-
lated at all. In contrast, NGF and gambo-
gic amide activated all three tyrosine
residues on TrkA receptor. Although tri-
mipramine induced TrkA phosphorylation
on Y794, it failed to induce phosphoryla-
tion on either Y490 or Y751 residues
(Figure 2B). K252a is an inhibitor of the Trk receptors. K252a
potently blocked amitriptyline-triggered TrkA tyrosine phosphor-
ylation, indicating that the stimulatory effect by amitriptyline
represents Trk receptor-dependent autophosphorylation. Strik-
ingly, amitriptyline, but not NGF, also induced TrkB tyrosine
phosphorylation, which was also blocked by K252a (Figure 2C).
However, amitriptyline failed to provoke TrkC activation (see
Figure S1 available online). Amitriptyline swiftly activated both
MAP kinase and Akt signaling cascades in hippocampal neurons
in a manner temporally similar to NGF (Figure 2D, left). Titration
assays demonstrated that 250 nM amitriptyline stimulated both
Erk1/2 and Akt signaling activation and the signal became
stronger at 500 nM (Figure 2D, right). Pretreatment with anti-
NGF or anti-BDNF failed to block the stimulatory effect of TrkA
or TrkB by amitriptyline in cortical neurons, suggesting that
amitriptyline provokes TrkA and TrkB activation independent of
neurotrophins (Figure S2). Together, these results demonstrate
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phorylation and activation in a dose-dependent manner.
Amitriptyline Induces Neurite Outgrowth in PC12 Cells
One of the most prominent neurotrophic effects of NGF is to
trigger neurite outgrowth in neuronal cells and incur differentia-
tion. To assesswhether amitriptyline and/or other antidepressant
drugs possess this activity, we incubated PC12 cells with NGF or
various antidepressant drugs (0.5 mM) for 5 days. As expected,
NGF induced pronounced neurite sprouting in PC12 cells after
5 days of treatment. Among all tested tricyclic antidepressant
drugs, only amitriptyline markedly triggered demonstrable neu-
rite outgrowth in PC12 cells, and the neurite network generated
was comparable to that initiated by NGF (Figure 3A). Titration
assays revealed that 100 nM amitriptyline was sufficient to
provoke substantial neurite sprouting in PC12 cells (Figure 3B).
Because PI3K and MAP kinase signaling pathways are required
Figure 3. Amitriptyline Provokes Neurite
Outgrowth in PC12 Cells
(A) Amitriptyline but not other tricyclic compounds
provokes neurite outgrowth in PC12 cells. PC12
cells were treated with amitriptyline and other
compounds (500 nM) for 5 days in 2% FBS and
1% HS medium. The drug-containing medium
was replenished every other day. Amitriptyline
induced neurite outgrowth as potently as NGF
(top). The relative neurite length was quantified
(bottom).
(B) Dose-dependent effect of neurite outgrowth.
Amitriptyline (100 nM) was able to provoke neurite
outgrowth in PC12 cells (One-way ANOVA, Bon-
ferroni post hoc test, *p < 0.01; **p < 0.005).
(C) K252a, PI3K, and MAP kinase inhibitors
abolish amitriptyline-provoked neurite outgrowth
in PC12 cells.
for NGF’s neurite outgrowth effect, we
performed experiments using pharmaco-
logical agents, including K252a, PI3K
inhibitors, and PD98058 (MEK1 inhibitor),
which all substantially blocked the neurite
outgrowth effect by NGF (Figure 3C).
These inhibitors also inhibited amitripty-
line’s neurotrophic activity, indicating
that amitriptyline’s neurite outgrowth
effect is Trk receptor dependent. Thus,
amitriptylinepossesses notable neurotro-
phic activity and robustly induces neurite
outgrowth.
Amitriptyline Binds TrkA and TrkB
Receptors and Triggers their
Dimerization and
Autophosphorylation
To determine whether Trk receptors
directly bind amitriptyline, we conducted
an in vitro binding assay with purified
Trk ECD and intracellular domain (ICD)
proteins and [3H]amitriptyline. Remark-
ably, the ECD but not ICD from TrkA and TrkB receptors bound
to amitriptyline, with TrkA exhibiting stronger binding (3 mM TrkA
binding constant and 14 mM TrkB) (Figure 4A). Gradual increase
of cold amitriptyline concentration progressively diminished
[3H]amitriptyline binding to the ECD of TrkA and TrkB receptors,
indicating specific binding (Figure 4B). In contrast, amitriptyline
was unable to compete with NGF or BDNF for binding to TrkA
or TrkB ECD, respectively (data not shown). This might be due
to its low affinity to the receptors. To map which region is
involved in TrkA binding to amitriptyline, we systematically
deleted Ig1, Ig2, and Ig1+2 domains in TrkA receptor and found
that none of the immunoglobulin-like domains were required for
the interaction with amitriptyline, while removal of the entire ECD
domain significantly diminished the binding by amitriptyline
(Figure 4C). Truncation assays with a variety of TrkA ECD
proteins showed that the first leucine-rich motif (LRM) (aa
72–97) was essential for full binding of amitriptyline to TrkA
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Amitriptyline Is a TrkA and TrkB Agonist(Figure 4D, bottom). Sequence alignment for the first LRM (aa
72–97) of Trk receptors is shown (Figure 4D, top).
We next sought to determine whether the binding by amitripty-
line to Trk receptors incurs their dimerization. Coimmunoprecipita-
tion demonstrated that amitriptyline, but not imipramine, elicited
TrkA homodimerization as NGF. Strikingly, amitriptyline uniquely
caused TrkA to heterodimerize with TrkB (Figure 4E, top). Amitrip-
tyline elicited marked tyrosine phosphorylation in TrkA and TrkB,
butnot inTrkCreceptorwhenHEK293cellswere individually trans-
fected by TrkA, TrkB, or TrkC (Figure 4F). In contrast, TrkA-KD
(kinase-dead) was not tyrosine phosphorylated, indicating that
tyrosine phosphorylation of Trk receptors provoked by amitripty-
line is exerted by the receptors themselves but not by any other
cytoplasmic tyrosine kinases. Hence, amitriptyline mimics NGF
and induces TrkA dimerization and autophosphorylation and also
possesses novel TrkA-TrkB heterodimerization activity.
Amitriptyline Activates TrkA and TrkB Receptors
and Prevents KA-Triggered Neuronal Apoptosis
in Mouse Brain
Toassesswhether amitriptylinecan induceTrk receptor activation
inmouse brain, we injected amitriptyline (15mg/kg, i.p.) intomice.
Amitriptyline induced both TrkA (Y794) and TrkB (Y816) activation
inmouse brain after 4 hr and the effect persisted at 8 hr (Figure 5A,
left top and third panels). In contrast, imipramine failed to activate
any of the receptors (Figure 5A, right). Consequently, we also
observed robust Akt and ERK1/2 activation with the same time
course, supporting that amitriptyline can provoke both TrkA and
TrkB receptor activation in mice. Although imipramine failed to
induce phosphorylation of the Trk receptors, it did promote phos-
phorylation of Akt and ERK1/2 (Figure 5A, right). The onset of Trk
receptor activation fits with the peak plasma concentration of
amitriptyline that is reached within 6 hr. RT-PCR analysis showed
that neither TrkA nor TrkB mRNA levels were altered after treat-
ment by amitriptyline or imipramine (Figure 5B), indicating that
acute treatment with amitriptyline or imipramine might not signifi-
cantly regulate Trk receptor transcription.
To explore whether amitriptyline can block the excitotoxicity
initiated by KA, we injected the mice with saline or amitriptyline
(15 mg/kg, i.p.), followed by saline or KA (25 mg/kg, i.p.). Five
days after treatment, TUNEL staining revealed significant
apoptosis in the hippocampus of KA-treated mice compared
to vehicle control or amitriptyline alone. KA-provoked apoptosis
was substantially diminished by pretreatment with amitriptyline,
while administration of amitriptyline after KA was not as effective(Figure 5C). Quantitative analysis revealed that amitriptyline sup-
pressed KA-induced cell death by 70% when injected prior to
KA, compared to 45% when injected after (Figure 5C, right).
Immunohistochemical analysis showed that TrkA and TrkB
were significantly activated in the hippocampus by amitriptyline.
In addition, amitriptyline evidently augmented the expression of
TrkA but not TrkB (Figure 5D). Hence, amitriptyline strongly
provokes TrkA and TrkB activation in mouse brain and protects
hippocampal neurons from KA-triggered cell death.
Amitriptyline Promotes TrkA and TrkB
Heterodimerization in Mouse Brain
To test whether amitriptyline regulates Trk receptor expression,
we fed the mice with various antidepressant drugs subchroni-
cally and chronically. After 5 or 28 days, we monitored TrkA
and TrkB protein expression levels and activation by immuno-
blotting. In 5 days, amitriptyline prominently provoked TrkA tyro-
sine phosphorylation, whereas imipramine, fluoxetine, and
control vehicle had no effect (Figure 6A, left top). TrkA expression
levels in amitriptyline-treated mice were higher than other drugs
or saline-treatedmice (left second panel). Remarkably, TrkBwas
activated by all three drugs compared to saline, and total TrkB
protein levels were higher in imipramine- and fluoxetine-treated
mice than in amitriptyline- and saline-treated mice (Figure 6A,
third and fourth panels). Compared to vehicle control and other
antidepressant drugs, RT-PCR analysis revealed that TrkA tran-
scription was substantially augmented after amitriptyline. Never-
theless, TrkB mRNA levels remained similar in all samples
(Figure 6A, right), indicating that subchronic treatment with anti-
depressant drugs does not significantly affect TrkB receptor
transcription. We made the similar observation in 28 day treated
samples (data not shown). The comparable effects were recapit-
ulated in 5-HT1a null mice, suggesting that serotonin receptor
5-HT1a is not implicated in these events (Figure S3). Thus, these
findings support the idea that amitriptyline activates TrkA
receptor and upregulates its expression in both subchronic
and chronic treatment conditions. However, imipramine and
fluoxetine are more potent than amitriptyline in provoking TrkB
activation and elevating TrkB protein levels.
Coimmunoprecipitation revealed that amitriptyline strongly
provoked endogenous TrkA to bind endogenous TrkB receptor
in the brain after subchronic treatment. In contrast, imipramine
or fluoxetine failed (Figure 6B). Cotransfection and pull-down
assays demonstrated that amitriptyline induced TrkA and TrkB
homodimerization like NGF and BDNF, but also triggeredFigure 4. Amitriptyline Binds TrkA and TrkB Receptors and Triggers their Dimerization and Autophosphorylation
(A) In vitro binding assaywith Trk recombinant proteins. [3H]Amitriptyline (0.1 mCi) was incubated with purified ECD and ICD recombinant proteins of Trk receptors
(5 mg each) at 30C for 1 hr. Themixture was subjected to filter/vacuum assay. After extensive washing, the filter paper was analyzed in liquid scintillation counter.
(B) Quantitative analysis of the binding between amitriptyline and TrkA and TrkB ECD. TrkA and TrkB ECD binding curve by [3H]amitriptyline (top). Scatchard plot
for Kd analysis (bottom left). Cold aminitryptyline competed with [
3H]amitriptyline for binding to TrkA or TrkB ECD (bottom right).
(C) ECD domain in TrkA is essential for amitriptyline to bind TrkA receptor.
(D) Amitriptyline associates with the first LRM in the N terminus of ECD of TrkA. Protein sequence alignment between the LRM motif from TrkA and the coun-
terparts from TrkB and TrkC (top). In vitro binding assay was conducted with a variety of fragments of TrkA ECD recombinant proteins (bottom). Data represent
mean ± SEM.
(E) Amitriptyline provokes TrkA dimerization. GFP-TrkA and HA-TrkA or HA-TrkB were respectively cotransfected into HEK293 cells and treated with 0.5 mM
amitriptyline or imipramine for 30 min. GFP-TrkA was immunoprecipitated with anti-GFP antibody, and the coprecipitated proteins were analyzed with anti-
HA antibody.
(F) Amitriptyline-triggered TrkA or TrkB tyrosine phosphorylation in HEK293 cells individually transfected by TrkA or TrkB, respectively. Kinase-dead TrkA
displayed negligible tyrosine phosphorylation.
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cells. In contrast, imipramine and fluoxetine did not induce either
of these effects (Figure 6C). To explore the role of amitriptyline
binding motifs in mediating TrkA and TrkB receptor heterodime-
rization, we deleted the binding motif and transfected the trun-
cated receptors into HEK293 cells. Deletion of amitriptyline
binding motif on TrkA completely abolished the homo- and
heterodimerization activity (Figure 6D, left). In contrast, trunca-
tion of the similar region on TrkB failed to abolish the stimulatory
activity by amitriptyline (Figure 6D, right), indicating that the
deleted fragment on TrkB might not be the binding spot for
amitriptyline. Notably, the cotransfected wild-type TrkA and
TrkB were potently phosphorylated by amitriptyline. Interest-
ingly, truncated TrkB but not deleted TrkA was still capable of
being activated by amitriptyline. In contrast, truncated TrkA
and TrkB were robustly activated by NGF or BDNF, respectively
(Figure 6D), suggesting that amitriptyline binding motif is not
required for neurotrophins to trigger Trk receptor activation.
Previous studies show that TrkA immunoglobulin-like ligand
binding domains inhibit spontaneous dimerization and activation
Figure 5. Amitriptyline Activates TrkA and
TrkB Receptors and Prevents KA-Triggered
Neuronal Apoptosis in Mouse Brain
(A) Amitriptyline but not imipramine activates TrkA
and TrkB receptors in mouse brain. Two- to three-
month-old C57BL/6 mice were intraperitoneally
injected with 15 mg/kg amitriptyline and 20 mg/
kg imipramine for various time points. Immuno-
blotting was conducted with various indicated
antibodies.
(B) Amitriptyline and imipramine do not alter TrkA
or TrkB transcription. RT-PCR analysis of TrkA and
TrkB in mouse brain.
(C) Amitriptyline diminishes KA-triggered hippo-
campal neuronal cell death. Two- to three-
month-old C57BL/6 mice were intraperitoneally
injected with 15 mg/kg amitriptyline either before
or after KA (25 mg/kg) administration. In 5 days,
the brain slides were analyzed with TUNEL assay.
Green shows apoptotic nuclei, which were also
stained with DAPI.
(D) Amitriptyline increases TrkA expression and
provokes TrkA and TrkB activation in hippo-
campus. Data represent mean ± SEM (n = 3/
group, One-way ANOVA, Bonferroni post hoc
test, *p < 0.01; **p < 0.01).
of the receptor (Arevalo et al., 2000). To
explore whether amitriptyline elicits
receptor dimerization via blocking the
autoinhibitory effect by the Trk receptors,
we transfected the truncated receptors
with different tags into HEK293 cells. Co-
transfection of truncated TrkA failed to
form a homodimer regardless of amitrip-
tyline (Figure S4A), supporting that
amitriptyline induces TrkA dimerization
not through blocking its autoinhibitory
effect by the binding motif on TrkA. In
contrast, amitriptyline elicited potent ho-
modimer by the truncated TrkB receptors as BDNF, though
TrkB activation by amitriptyline was evidently reduced as
compared to BDNF. Ligand binding assays demonstrated that
deletion of 72–97 residues abolished the binding activity by
amitriptyline on TrkA but not on TrkB (Figures S4B and S4C).
This finding might explain why the truncated TrkB is still able to
form a homodimer by amitriptyline. Hence, Trk receptor binding
by amitriptyline is essential for the receptor homo- and heterodi-
merization.
Investigation of Amitriptyline Role in Prevention of
Neuronal Apoptosis Reveals Distinct Effect on TrkA and
TrkB
To assess whether amitriptyline’s neurotrophic activity is solely
mediated through TrkA receptor, we explored its ability to
promote neuronal survival in wild-type neurons and those that
lack TrkA. Heterozygous (TrkA +/) males and females were
crossed and hippocampal neurons were harvested from
newborn (P0) pups. Amitriptyline triggered TrkA tyrosine phos-
phorylation in wild-type but not TrkA knockout neurons
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sine phosphorylation in both TrkA and TrkB receptor in a TrkA-
dependent manner (Figure 7A, right second and fourth panels).
Interestingly, these experiments additionally revealed a different
effect of amitriptyline on TrkB in the absence of TrkA. In contrast
to TrkA, amitriptyline activated TrkB in both wild-type and
TrkA / neurons, indicating that TrkA is not required for
amitriptyline-induced phosphorylation of TrkB and amitriptyline
activates TrkB in a TrkA-independent way.
We next assessed the apoptotic pathway by examining cas-
pase-3 activation at baseline and following glutamate exposure.
In the absence of glutamate treatment, a low amount of active
caspase-3 was demonstrable in TrkA null neurons but absent
in wild-type neurons, consistent with the substantial neuronal
cell death that has been observed in TrkA null mice (Smeyne
et al., 1994). Amitriptyline completely inhibited the basal cas-
pase-3 activation in TrkA/ neurons (Figure 7A, left fifth panel).
Caspase-3 activation by glutamate was moderately enhanced in
TrkA / neurons, suggesting that TrkA normally inhibits the
apoptotic response to excitotoxicity. Amitriptyline pretreatment
partially blocked glutamate-induced caspase-3 activation in
both wild-type and TrkA/ neurons, suggesting that activation
of TrkB by amitriptyline in TrkA / neurons contributes to this
protective action. Neither fluoxetine nor imipramine inhibited
caspase-3 activation in wild-type or TrkA / neurons
(Figure 7A, right fifth panel). To determine whether activation of
TrkA by amitriptyline requires TrkB, we extended our analysis
to TrkB / neurons. Amitriptyline, but not imipramine, selec-
tively activated TrkA in both wild-type and TrkB / neurons
(Figure 7B, third panel). Depletion of TrkB incurred spontaneous
caspase-3 activation, which was completely blocked by amitrip-
tyline but not imipramine. Moreover, amitriptyline also markedly
suppressed glutamate-provoked caspase-3 activation in both
wild-type and TrkB / neurons, whereas imipramine had no
protective effect (Figure 7B, bottom). These results indicate
that the activation of TrkA by amitriptyline is independent of
TrkB and TrkA activation in TrkB / neurons might account
for the protective effect of amitriptyline pretreatment.
TrkA F592A knockin mice can be selectively blocked by the
inhibitor 1NMPP1, which results in Trk null phenotypes (Chen
et al., 2005). Consistent with previous reports, NGF-provoked
TrkA, Akt, and Erk1/2 phosphorylation was selectively blocked
by 1NMPP1 but not K252a, a pattern that was mimicked by
amitriptyline treatment (Figure 7C). Imipramine and fluoxetine
failed to activate TrkA but did stimulate Akt and Erk1/2, although
these activities were not blocked by 1NMPP1 or K252a, indi-
cating that these antidepressants were acting via a TrkA-inde-
pendent pathway (Figure 7C, third and fifth panels).
We next tested whether our in vitro results could be recapitu-
lated in vivo by assessing KA-induced caspase-3 activation in
TrkA F592A mice. As expected, 1NMPP1, amitriptyline alone,
or 1NMPP1 + amitriptyline combined treatment had no effect
on caspase-3 in TrkA F592A mice. KA provoked significant cas-
pase-3 activation that was suppressed by amitriptyline and this
protective effect was abolished by 1NMPP1 pretreatment
(Figure 7D, top). 1NMPP1 also blocked TrkA F592A phosphory-
lation by amitriptyline and imipramine did not activate TrkA under
any condition (Figure 7D, middle). KA-provoked caspase-3 acti-
vation in 1NMPP1-sensitive TrkB F616A knockin mice was alsoChemistry & Biology 16,inhibited by amitriptyline. However, in contrast to the TrkA
F592A mice, this protective effect persisted in the presence of
1NMPP1 (Figure 7E). Although imipramine weakly activated
TrkB F616A, it failed to suppress caspase-3 activation by KA
(Figure 7E). These results demonstrate that amitriptyline selec-
tively activates both TrkA and TrkB receptors in mice, but TrkA
is more important than TrkB in mediating the neuronal survival
functions by amitriptyline.
DISCUSSION
In this study, we show that amitriptyline binds to a motif in the
first LRM in the TrkA receptor ECD with a Kd of 3 mM. Interest-
ingly, amitriptyline also interacts with the ECD from TrkB but not
TrkC with a decreased binding affinity (Kd 14 mM). A previous
study suggests that brain [amitriptyline] in treating depression
is around 5–7 mm (Glotzbach and Preskorn, 1982). To treat
pain associated peripheral neuropathy, [amitriptyline] is 2-fold
lower (Esser and Sawynok, 1999). Hence, amitriptyline affinity
to TrkA might be sufficient to exert its biological actions. The
known Kd for NGF to TrkA and BDNF to TrkB is 1 nM in the
absence of p75NTR. These differences in binding affinities are
consistent with the quantitative dose-response studies that
amitriptyline is some 100-fold less potent than the neurotrophin
ligands (Figure 3).
NGF is a homodimer and it binds to both the Ig2 and LRM
domain on TrkA and brings two TrkA receptors together, which
subsequently autophosphorylate each other. NGF selectively
binds the 24 amino acids (aa 97–120) of the second LRM with
a Kd of 1.3 nM (O’Connell et al., 2000). Here we show that
amitriptyline can only bind the first LRM domain (aa 72–97) and
promotes TrkA receptor dimerization. In addition, we also
show that amitriptyline binds both TrkA and TrkB receptors
and provokes TrkA to interact with TrkB, leading to a hetero-
dimer. However, NGF fails to do so (Figure 4). Previous studies
show that BDNF, NT-3, and NT-4 bind to the LRM3 cassette of
TrkB, whereas NGF does not. These binding characteristics
clearly reflect in vivo specificities. A more precise mapping of
the regions responsible for binding BDNF, NT-3, and NT-4 iden-
tified the second LRM of TrkB as a functional unit capable of
binding all three neurotrophins (Windisch et al., 1995). Why
does amitriptyline but not NGF or BDNFprovoke the heterodimer
formation by TrkA and TrkB?NGF andBDNF bind p75NTR,while
amitriptyline does not (data not shown), suggesting that these
two categories of molecules bind neurotrophin receptors in
fundamentally different ways.
Antidepressant drugs and electroconvulsive stimuli signifi-
cantly influence brain neurotrophin concentrations. It has been
proposed that BDNF and NGFmay play a role in depression (An-
gelucci et al., 2000). Subchronic treatment with lithium increases
NGF content in brain of adult rat, supporting that NGF may be
implicated in the mechanism of antibipolar treatments (Hellweg
et al., 2002). To test whether amitriptyline exerts its antidepres-
sant action through the TrkA receptor, we conducted forced
swim tests with TrkA F592A mice. Blocking TrkA signaling with
1NMPP1 did not significantly alter the immobility. Subchronic
treatment of mice with amitriptyline or imipramine substantially
decreased the immobility no matter whether TrkA receptor was
blocked or not. Moreover, both drugs exhibited demonstrable644–656, June 26, 2009 ª2009 Elsevier Ltd All rights reserved 651
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TrkA signalingmight be dispensable for at least some of the ther-
apeutic actions of amitriptyline. This finding fits with previous
reports that amitriptyline increased BDNF but not NGF concen-
tration in serum of depressed patients (Hellweg et al., 2008).
Moreover, normal TrkB signaling is required for the behavioral
effects typically produced by antidepressants (Saarelainen
et al., 2003). Conceivably, amitriptyline exerts its antidepressant
action through TrkB but not TrkA receptor.
While tricyclics are generally regarded as comparable antide-
pressants, why is amitriptyline uniquely effective versus the other
tricyclics? Imipramine differs chemically fromamitriptyline only in
the presence of an exocyclic double bond in amitriptyline, which
is absent in imipramine (Figure 1A). The exocyclic double bond
inhibits the free rotation of the side chain of amitriptyline,
rendering it slightly more ‘‘rigid.’’ Thus, this chemical feature
may account for the selective and potent Trk agonistic activity
of amitriptyline. Consistently, it has been shown before that
amitriptyline but not imipramine possesses robust anticholin-
ergic activity (Snyder andYamamura, 1977). Tricyclic antidepres-
sants like amitriptyline inhibit the monoamine reuptake inactiva-
tion of norepinephrine and serotonin neurotransmitters. They
are potent blockers ofmuscarinic cholinergic (Snyder and Yama-
mura, 1977), alpha adrenergic, and5-HT receptors (Peroutka and
Snyder, 1980). To explore whether serotonin is implicated in
amitriptyline’s action, we depleted serotonin with pCPA and
found that amitriptyline’s stimulatory effect on TrkA was not
significantly affected. Moreover, serotonin itself was unable to
provoke TrkA or TrkA activation in primary neurons (data not
shown), suggesting that serotonin might not be implicated in
amitriptyline’s agonistic effect. Amitriptyline has anticholinocep-
tor actions on both the CNS and peripheral organs. The best
correlation to the biological activity of amitriptyline is the anticho-
linergic actions. For instance, inhibition of nAChRs by mecamyl-
amine had antidepressant-like effects and potentiated the
antidepressant activity of amitriptyline when the two drugs
were used in combination. Mice lacking high-affinity nAChRs
showed no behavioral response to amitriptyline. Hence, the
antagonism of nAChRs might be an essential component of the
therapeutic action of antidepressants like amitriptyline (Caldar-
one et al., 2004). In alignment with this finding, we show that
mecamylamine also strongly elicited neurite sprouting processes
in PC12 cells (Figure S6). Our data demonstrate that amitripty-
line exhibits potent neurotrophic activities including neurite
outgrowth in PC12 cells, neuronal survival in primary neurons,
and neuroprotection in mice, which mimic the primary neurotro-
phic effects of NGF. It is also noteworthy that amitriptyline effec-
tively treats chronic neuropathic pain (Ho et al., 2008; Watson,2000). Unlike NGF, which causes intense pain, conceivably,
amitriptyline achieves its pain-reducing effects and might be
entirely distinct from NGF/TrkA mechanisms involving peripheral
nerves.
SIGNIFICANCE
Neurotrophins exert the physiological functions through
provoking neurotrophin receptor (TrkA, TrkB, and TrkC)
homodimerization. However, it remains elusive whether the
ligand has to be a homodimer in order to trigger the receptor
dimerization. Moreover, it is unknown whether the Trk
receptors can form a heterodimer or not. In the current
study, we show that the small tricyclic antidepressant drug
amitriptyline provokes both TrkA and TrkB homo- and heter-
odimerization and activation in transfected HEK293 cells
and primary neurons. Amitriptyline elicits potent TrkA and
TrkB activation inmicewith a similar temporal pattern. Thus,
we demonstrate that amitriptyline acts as a novel agonist
for both TrkA and TrkB. Strikingly, this small molecule but
not any other antidepressant drugs selectively stimulates
endogenous TrkA/TrkB heterodimer formation in mouse
brain. This finding provides amolecular mechanism in dime-
rization and activation of transmembrane receptor tyrosine
kinase. Endogenous cognate ligands for Trk receptors are
homodimers, which can only selectively bind to one of the
Trk receptors, whereas amitriptyline binds to both TrkA
and TrkB receptors, leading to a heterodimer formation.
Hence, this discovery establishes a proof-of-concept model
for identifying small molecular agonists and antagonists for
receptor tyrosine kinase. Conceivably, using the established
screening assay, numerous small compounds can be iden-
tified for mimicking growth factors including EGF, insulin,
netrins, etc.
EXPERIMENTAL PROCEDURES
Cells, Reagents, and Mice
Mouse septal neuron 3 neuroblastoma hybrid SN56 cells were created by
fusing N18TG2 neuroblastoma cells with murine (strain C57BL/6) neurons
from postnatal day 21 septa. SN56 cells were maintained at 37C with 5%
CO2 atmosphere in DMEM containing 1mMpyruvate and 10%FBS. T17 cells,
stably transfected with rat TrkA, were cultured in the same medium containing
300 mg/ml G418. NGF and BDNF were purchased from Roche. The specificity
of anti-p-TrkA 794 has been previously described (Jeanneteau et al., 2008;
Rajagopal et al., 2004). The specificity of anti-p-TrkB 816 has been described
before (Arevalo et al., 2006). Anti-TrkB antibody was obtained from Biovision.
Anti-TrkA was obtained from Cell Signaling. The chemical library containing
2000 biologically active compoundswas from the SpectrumCollection (Micro-
Source Discovery System, Inc.). TrkAF592A and TrkBF616A mice have beenFigure 6. Amitriptyline Promotes TrkA and TrkB Heterodimerization in Mouse Brain
(A) Amitriptyline provokes TrkA phosphorylation and upregulates its expression mice. Two- to three-month-old mice were intraperitoneally injected with various
antidepressant drugs for 5 days. The doses were 15 mg/kg, 20 mg/kg, and 25 mg/kg for amitriptyline, imipramine, and fluoxetine, respectively.
(B) Amitriptyline triggers TrkA and TrkB receptor heterodimerization in mouse brain. Wild-type and 5-HT1a null mice were treated with various antidepressant
drugs for 5 days. TrkA was immunoprecipitated, and its coprecipitated proteins were analyzed by immunoblotting.
(C) Amitriptyline elicits TrkA and TrkB receptor homo- and heterodimerization. Differentially tagged TrkA and TrkB receptors were cotransfected into HEK293
cells and treated with various antidepressant drugs for 30 min. Data represent mean ± SEM of n = 3.
(D) Amitriptyline binding motif on TrkA is essential for Trk receptor homo- and heterodimerization. HA-tagged TrkA or TrkB was cotransfected with GST-DTrkA or
GST-DTrkB into HEK293 cells, followed byNGF, BDNF, amitriptyline, or imipramine treatment. Truncated TrkA or TrkBwas pulled down by glutathione beads and
monitored by anti-HA antibody.
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TrkA +/, TrkB +/, and NGF +/ C57BL/6 mice were bred in a pathogen-
free environment in accordance with Emory Medical School guidelines. All
chemicals not included above were purchased from Sigma.
Cell-Based Screen
T17 cells were seeded in a 96 well plate at 10,000 cells/well in 100 ml of
complete medium. Cells were incubated overnight, followed by 30 min
pretreatment with 10 mM compounds in DMSO (10 mM stock concentration
was obtained from the Spectrum Collection library). The cells were then
treated with 1 mM staurosporine for 9 hr. One hour before the termination of
the experiment, 10 mM MR(DEVD)2, a cell permeable caspase-3-activated
fluorescent dye, was introduced. Cells were fixed with 4% paraformaldehyde
for 15 min. Cells were washed with PBS and incubated with 1 mg/ml Hoechst
33342 for 10 min. Cover slides were washed with PBS, mounted, and exam-
ined using a fluorescence microscope.
Binding Constant Determination
Purified TrkA ECD or ICD proteins were incubated with different [3H-amitripty-
line] at 4C for 10min in 1ml of binding buffer (50mMNa-K phosphate [pH 7.1],
200 mM NaCl, and 2 nM 3H-amitriptyline [68,000 cpm]). After the incubation,
the reaction mixture was loaded on filter paper. The mixture was washed
with 3 3 5 ml of washing buffer (100 mM Tris [pH 7.1]). The dried filter paper
was put into a small vial and subjected to liquid scintillation counter analysis.
The value of the dissociate constant and the number of sites were obtained
from Scatchard plots by using the equation r/[L]free = n/Kd  r/Kd, where r is
the ratio of the concentration of bound ligand to the total protein concentration
and n is the number of binding sites.
KA/Amitriptyline Drug Administration
Male C57BL/6 mice aged 60 days were injected intraperitoneally with a single
dose of either 30% ethanol in saline or KA (25 mg/kg) (Sigma) or 7,8-dihydrox-
yflavone (5 mg/kg) followed by KA. Animals were continually monitored for 2 hr
for the onset of seizure activity. At 5 days after treatment, animals were anes-
thetized and perfused with 4% paraformaldehyde in 0.1 M phosphate-buff-
ered saline. Brains were removed, post-fixed overnight, and processed for
paraffin embedding. Serial sections were cut at 5 mm and mounted on slides
(Superfrost-plus; Fisher). The slides were processed for TUNEL staining to
assess the degree of DNA fragmentation.
Immunohistochemistry Staining
Brain tissues were fixed in 4% paraformaldehyde overnight followed by
paraffin embedding. Sections of 6 mm were cut. For immunohistochemical
staining, brain sections were deparaffinized in xylene and rehydrated in graded
alcohols. Endogenous peroxidase activity was blocked by 3% hydrogen
peroxide for 5 min and all slides were boiled in 10 mM sodium citrate buffer
(pH 6.0) for 10 min. Phosphorylated TrkA, TrkA, phosphorylated TrkB, and
TrkB were detected using specific antibodies and Zymed Histo-SP AEC kit
(Invitrogen). Slides were then counterstained with hematoxylin.
TrkA F592A and TrkB F616A Mice Treatment with KA
Two- to four-month-old TrkAF592A and TrkBF616Amice were pretreated with
1NMPP1 in drinking water (25 mM) 1 day before amitriptyline (15 mg/kg) treat-
ment. After 4 hr, KA (25mg/kg) was intraperitoneally injected into themice. Themice were housed for an additional 4 days with 1NMPP1 in the drinking water.
At day 5, animals were anesthetized and perfused and treated as described
above. The brain slides were processed for TUNEL staining to assess the
degree of DNA fragmentation.
SUPPLEMENTAL DATA
Supplemental Data include six figures and can be found with this article online at
http://www.cell.com/chemistry-biology/supplemental/S1074-5521(09)00177-X.
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